Who are secretin, biologically derived porcine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chirhostim, ChiRhoStim, RESMETIROM, Skytrofa, Orgovyx, Guna-Geriatrics.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/secretin-biologically-derived-porcine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

secretin, biologically derived porcine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

secretin, biologically derived porcine (secretin, biologically derived porcine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: hormone. Area: Gastroenterology.

phase 3 hormone secretin receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

secretin, biologically derived porcine (secretin, biologically derived porcine) — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Secretin is a hormone that stimulates the pancreas to release digestive enzymes and bicarbonate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
secretin, biologically derived porcine TARGET	secretin, biologically derived porcine	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	phase 3	hormone	secretin receptor
Chirhostim	Secretin Human	Chirhoclin	marketed	Secretin-class Hormone	Secretin receptor	2002-01-01
ChiRhoStim	ChiRhoStim	ChiRhoClin, Inc.	marketed	Secretin receptor agonist	Secretin receptor
RESMETIROM	RESMETIROM		marketed	Thyroid Hormone Receptor beta Agonist [EPC]		2024-01-01
Skytrofa	LONAPEGSOMATROPIN	Ascendis Pharma Encocrinology Div A/S	marketed	Recombinant Human Growth Hormone [EPC]	Growth hormone receptor	2021-01-01
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Guna-Geriatrics	BARIUM	Bracco	marketed	Adrenocorticotropic Hormone [EPC]		2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (hormone class)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). secretin, biologically derived porcine — Competitive Intelligence Brief. https://druglandscape.com/ci/secretin-biologically-derived-porcine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab